Marker Therapeutics (MRKR) Competitors $1.60 +0.03 (+1.91%) Closing price 04:00 PM EasternExtended Trading$1.50 -0.11 (-6.56%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. SRZN, IMMX, INCR, ABOS, IMUX, GNTA, VNRX, ANEB, PYXS, and ADAPShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Surrozen (SRZN), Immix Biopharma (IMMX), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Genenta Science (GNTA), VolitionRx (VNRX), Anebulo Pharmaceuticals (ANEB), Pyxis Oncology (PYXS), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Its Competitors Surrozen Immix Biopharma InterCure Acumen Pharmaceuticals Immunic Genenta Science VolitionRx Anebulo Pharmaceuticals Pyxis Oncology Adaptimmune Therapeutics Surrozen (NASDAQ:SRZN) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has preferable valuation & earnings, SRZN or MRKR? Marker Therapeutics has lower revenue, but higher earnings than Surrozen. Marker Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.65M6.75-$63.56M-$24.96-0.34Marker Therapeutics$6.59M2.75-$10.73M-$1.33-1.20 Is SRZN or MRKR more profitable? Surrozen has a net margin of 0.00% compared to Marker Therapeutics' net margin of -224.46%. Marker Therapeutics' return on equity of -101.87% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -842.90% -71.32% Marker Therapeutics -224.46%-101.87%-83.02% Does the media refer more to SRZN or MRKR? In the previous week, Marker Therapeutics had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Marker Therapeutics' score of 0.94 indicating that Surrozen is being referred to more favorably in the media. Company Overall Sentiment Surrozen Very Positive Marker Therapeutics Positive Which has more risk & volatility, SRZN or MRKR? Surrozen has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Do analysts recommend SRZN or MRKR? Surrozen currently has a consensus target price of $38.50, indicating a potential upside of 358.33%. Marker Therapeutics has a consensus target price of $13.17, indicating a potential upside of 722.92%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Do insiders & institutionals have more ownership in SRZN or MRKR? 66.6% of Surrozen shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 43.5% of Surrozen shares are owned by insiders. Comparatively, 14.5% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummarySurrozen and Marker Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.10M$2.44B$5.57B$9.31BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-1.209.1928.6119.73Price / Sales2.75587.68412.00173.26Price / CashN/A164.3436.0257.96Price / Book0.924.698.235.67Net Income-$10.73M$30.99M$3.23B$257.79M7 Day Performance-11.60%0.60%-0.01%0.52%1 Month Performance5.26%7.93%5.61%8.84%1 Year Performance-72.65%-5.48%26.52%14.18% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.4872 of 5 stars$1.60+1.9%$13.17+722.9%-71.8%$18.10M$6.59M-1.2060SRZNSurrozen2.7519 of 5 stars$8.35-0.1%$38.50+361.1%-10.0%$71.58M$10.65M-0.3380Gap UpIMMXImmix Biopharma3.5672 of 5 stars$2.62+2.7%$7.00+167.2%+35.3%$71.09MN/A-3.749INCRInterCure0.6726 of 5 stars$1.50-3.8%N/A-37.4%$71.09M$66.28M0.00350News CoverageHigh Trading VolumeABOSAcumen Pharmaceuticals3.0034 of 5 stars$1.16flat$6.33+446.0%-54.7%$70.26MN/A-0.6020News CoverageIMUXImmunic2.4817 of 5 stars$0.77+5.2%$11.60+1,416.3%-38.7%$69.68MN/A-0.6270GNTAGenenta Science2.5999 of 5 stars$3.98+4.7%$25.00+528.1%+10.0%$69.50MN/A0.007Gap UpVNRXVolitionRx2.1035 of 5 stars$0.67-9.0%$3.50+419.8%-1.0%$69.38M$1.31M-1.8780News CoverageGap UpANEBAnebulo Pharmaceuticals2.7163 of 5 stars$1.65-2.1%$5.50+234.3%-35.1%$69.02MN/A-6.334Positive NewsGap UpHigh Trading VolumePYXSPyxis Oncology2.1075 of 5 stars$1.14+3.6%$9.00+689.5%-63.8%$68.14M$16.15M-0.7260ADAPAdaptimmune Therapeutics1.9587 of 5 stars$0.24-3.6%$1.35+460.6%-78.1%$66.26M$178.03M-0.89490 Related Companies and Tools Related Companies Surrozen Alternatives Immix Biopharma Alternatives InterCure Alternatives Acumen Pharmaceuticals Alternatives Immunic Alternatives Genenta Science Alternatives VolitionRx Alternatives Anebulo Pharmaceuticals Alternatives Pyxis Oncology Alternatives Adaptimmune Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRKR Stock Alerts